{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:49:39Z","timestamp":1793198979890,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.therap.2020.02.012","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:37:41Z","timestamp":1581593861000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres"],"prefix":"10.1016","volume":"75","author":[{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie-Pierre","family":"Jonville-Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.02.012_bib0265","series-title":"VigiBase","author":"Uppsala Monitoring Centre","year":"2019"},{"issue":"6","key":"10.1016\/j.therap.2020.02.012_bib0270","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/fcp.12314","article-title":"Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology","volume":"31","author":"Micallef","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.02.012_bib0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.therap.2016.02.028","article-title":"Pharmacovigilance fran\u00e7aise: missions, organisation et perspectives","volume":"71","author":"Vial","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.02.012_bib0280","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2006.00441.x","article-title":"Valvular heart disease in a patient taking benfluorex","volume":"20","author":"Noize","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.02.012_bib0285","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/QAD.0000000000000789","article-title":"Psychiatric disorders after starting dolutegravir: report of four cases","volume":"29","author":"Kheloufi","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2020.02.012_bib0290","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jns.2019.01.018","article-title":"Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database","volume":"398","author":"Lacroix","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.therap.2020.02.012_bib0295","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s11096-018-0712-y","article-title":"Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension","volume":"40","author":"Chaumais","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.therap.2020.02.012_bib0300","doi-asserted-by":"crossref","first-page":"1802472","DOI":"10.1183\/13993003.02472-2018","article-title":"Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance\u2013pharmacodynamic study","volume":"53","author":"Cornet","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.therap.2020.02.012_bib0305","series-title":"Orphanet","year":"2019"},{"key":"10.1016\/j.therap.2020.02.012_bib0310","first-page":"785","article-title":"Eosinophilia-myalgia syndrome and L-tryptophan-containing products \u2013 New Mexico, Minnesota, Oregon, and New York, 1989","volume":"38","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.therap.2020.02.012_bib0315","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1001\/jama.1989.03430220033006","article-title":"From the Centers for Disease Control. Eosinophilia-myalgia syndrome \u2013 New Mexico","volume":"262","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.02.012_bib0320","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0140-6736(90)90421-Z","article-title":"L-tryptophan and eosinophilia-myalgia syndrome in New Mexico","volume":"335","author":"Eidson","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2020.02.012_bib0325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jama.1990.03450020065028","article-title":"Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer","volume":"264","author":"Slutsker","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.02.012_bib0330","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199003293221302","article-title":"Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan","volume":"322","author":"Silver","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.02.012_bib0335","first-page":"355","article-title":"\u201cEosinophilia-myalgia\u201d syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases","volume":"46","author":"Castot","year":"1991","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.02.012_bib0340","series-title":"Arr\u00eat\u00e9 du 4 janvier 1990 portant suspension de la fabrication, de l\u2019importation, de la mise sur le march\u00e9 et ordonnant le retrait des produits comportant comme ingr\u00e9dient unique ou majoritaire du L. tryptophane","year":"1990"},{"key":"10.1016\/j.therap.2020.02.012_bib0345","series-title":"National Institute for Health and Welfare recommends discontinuation of Pandemrix vaccination","year":"2010"},{"key":"10.1016\/j.therap.2020.02.012_bib0350","series-title":"Current information on the investigation of cases of narcolepsy after vaccination with Pandemrix","year":"2010"},{"key":"10.1016\/j.therap.2020.02.012_bib0355","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/sleep\/33.11.1428","article-title":"Post-H1N1 narcolepsy-cataplexy","volume":"33","author":"Dauvilliers","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.therap.2020.02.012_bib0360","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","article-title":"The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns","volume":"31","author":"Wijnans","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2020.02.012_bib0365","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.therap.2020.02.012_bib0370","doi-asserted-by":"crossref","first-page":"e33723","DOI":"10.1371\/journal.pone.0033723","article-title":"Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland","volume":"7","author":"Partinen","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.therap.2020.02.012_bib0375","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2807\/1560-7917.ES2014.19.17.20789","article-title":"Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010","volume":"19","author":"O\u2019Flanagan","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.therap.2020.02.012_bib0380","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/dmcn.12522","article-title":"Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine in England","volume":"56","author":"Winstone","year":"2014","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.therap.2020.02.012_bib0385","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/awt187","article-title":"Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France","volume":"136","author":"Dauvilliers","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.therap.2020.02.012_bib0390","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1051\/medsci\/20143012017","article-title":"Narcolepsy with cataplexy: an autoimmune disease?","volume":"30","author":"Jacob","year":"2014","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.therap.2020.02.012_bib0395","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2013.02.003","article-title":"Genetic association, seasonal infections and autoimmune basis of narcolepsy","volume":"43","author":"Singh","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.therap.2020.02.012_bib0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5665\/sleep.3300","article-title":"DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe","volume":"37","author":"Tafti","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.therap.2020.02.012_bib0405","series-title":"Avis relatif aux caract\u00e9ristiques des futurs vaccins pand\u00e9miques","author":"Haut Conseil de la Sant\u00e9 Publique","year":"2013"},{"key":"10.1016\/j.therap.2020.02.012_bib0410","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-154-7-201104050-00004","article-title":"The Systemic Capillary Leak Syndrome: A Case Series of 28 Patients From a European Registry","volume":"154","author":"Gousseff","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.therap.2020.02.012_bib0415","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CJI.0b013e31821dcb50","article-title":"Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome","volume":"34","author":"Samlowski","year":"2011","journal-title":"J Immunother"},{"key":"10.1016\/j.therap.2020.02.012_bib0420","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00205236","article-title":"Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice","volume":"28","author":"Puri","year":"1989","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.therap.2020.02.012_bib0425","first-page":"1445","article-title":"G-CSF related capillary leak syndrome in a child with leukemia","volume":"42","author":"Dagdemir","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.therap.2020.02.012_bib0430","series-title":"Filgrastim (Neupogen\u00ae) et Pegfilgrastim (Neulasta\u00ae)\u00a0: risque de syndrome de fuite capillaire chez les patients atteints d\u2019un cancer et chez les donneurs sains\u2013Lettre aux professionnels de sant\u00e9","year":"2013"},{"key":"10.1016\/j.therap.2020.02.012_bib0435","series-title":"Risque de syndrome de fuite capillaire associ\u00e9 au lenograstim (Granocyte\u00ae) chez les patients atteints d\u2019un cancer et chez les donneurs sains - Lettre aux professionnels de sant\u00e9","year":"2014"},{"key":"10.1016\/j.therap.2020.02.012_bib0440","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.revmed.2014.11.005","article-title":"Idiopathic and secondary capillary leak syndromes: a systematic review of the literature","volume":"36","author":"Duron","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2020.02.012_bib0445","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2020.02.012_bib0450","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.02.012_bib0455","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0609.2011.01636.x","article-title":"Pathophysiology of acquired von Willebrand disease: a concise review","volume":"87","author":"Shetty","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.therap.2020.02.012_bib0460","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.medcli.2016.11.030","article-title":"Hemofilia adquirida: epidemiolog\u00eda, cl\u00ednica, diagn\u00f3stico y tratamiento","volume":"148","author":"Mingot-Castellano","year":"2017","journal-title":"Medicina Cl\u00ednica"},{"key":"10.1016\/j.therap.2020.02.012_bib0465","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/MBC.0b013e32832fb1b9","article-title":"Acquired factor VIII inhibitors: case reports of paclitaxel and penicillin-induced entities","volume":"20","author":"El-Osta","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.therap.2020.02.012_bib0470","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/QAD.0b013e3280b07b7d","article-title":"Acquired factor VIII inhibitor in an HIV-infected patient after treatment with pegylated interferon-alpha 2a and ribavirin","volume":"21","author":"Paul","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2020.02.012_bib0475","first-page":"RA55","article-title":"Drug-induced anti-factor VIII antibodies: a systematic review","volume":"13","author":"Franchini","year":"2007","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.therap.2020.02.012_bib0480","first-page":"143","article-title":"Acquired von Willebrand's disease, IgE polyclonal gammopathy and griseofulvin therapy","volume":"41","author":"Conrad","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.therap.2020.02.012_bib0485","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ajh.2830490114","article-title":"Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: evidence for heightened proteolysis of von Willebrand factor","volume":"49","author":"Castaman","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.therap.2020.02.012_bib0490","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00005373-196709000-00013","article-title":"Hydroxyethyl starch (HES) and bleeding. An experimental investigation of its effect on hemostasis","volume":"7","author":"Garzon","year":"1967","journal-title":"J Trauma"},{"key":"10.1016\/j.therap.2020.02.012_bib0495","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJM200108233450818","article-title":"Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch","volume":"345","author":"Jonville-B\u00e9ra","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.02.012_bib0500","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s001340101107","article-title":"Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200\/0.5\/6) in healthy human subjects","volume":"27","author":"de Jonge","year":"2001","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.therap.2020.02.012_bib0505","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1213\/00000539-200302000-00012","article-title":"The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markers","volume":"96","author":"Jones","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.therap.2020.02.012_bib0510","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s001340050833","article-title":"An international view of hydroxyethyl starches","volume":"25","author":"Treib","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.therap.2020.02.012_bib0515","series-title":"Hydroxyethylamidons. Communiqu\u00e9 de Presse ANSM","year":"1999"},{"key":"10.1016\/j.therap.2020.02.012_bib0520","first-page":"2716","article-title":"Ketamine-induced bladder dysfunction is associated with extracellular matrix accumulation and impairment of calcium signaling in a mouse model","volume":"19","author":"Shen","year":"2019","journal-title":"Mol Med Rep"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:27Z","timestamp":1758567207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0040595720300172"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.012","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}